ClinicalTrials.gg
RecruitingNCT02285582IRHDRUpdated Nov 19, 2026

International Rare Histiocytic Disorders Registry (IRHDR)

An observational study in Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD), sponsored by The Hospital for Sick Children. Recruiting at 15 sites in 9 countries. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Hospital for Sick Children · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
400
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Erdheim-Chester Disease with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Erdheim-Chester Disease · United States.

Started
2014
with 1 other
Observational
8 of 15
5 open now
Registered
4th of 15
by date

Among the 15 studies in Erdheim-Chester Disease with a site in United States, this one is one of 2 that started in 2014, is one of 8 observational ones, and was the 4th registered.

Erdheim-Chester Disease

22 studies on the registry are indexed under Erdheim-Chester Disease; 11 are open to participants now.

Browse Erdheim-Chester Disease studies →

Open to participants now

7 of the 15 studies in Erdheim-Chester Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Erdheim-Chester Disease studies recruiting now, 8 (73%) set no upper age limit and 1 (9%) stops at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Erdheim-Chester Disease with a site in United States, or all of them as a file.
02

Study summary

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.

Read the detailed description

Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontaneously, to progressive disseminated forms that can be debilitating and sometimes life-threatening. The rare histiocytic disorders (RHD), or non-Langerhans cell disorders, are a diverse group of disorders defined by the accumulation of histiocytes that do not meet the criteria for Langerhans cell histiocytosis (LCH) or hemophagocytic lymphohistiocytosis (HLH). They include: Juvenile xanthogranuloma family, Erdheim-Chester disease, Multifocal Reticulohistiocytosis, Rosai-Dorfman disease and the Malignant Histiocytoses. Since they are so rare, there is limited understanding of their causes and treatments. Physicians, patients and parents of children with rare histiocytoses frequently consult members of the Histiocyte Society on the management of these disorders. Very often, no specific recommendation about treatment can be made due to the lack of prospective outcome data for these rare entities. The creation of an International Rare Histiocytic Disorders Registry (IRHDR) will facilitate a uniform diagnosis of the RHD's, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry will also provide expert pathology reviews and may lead to future therapeutic recommendations. Furthermore, the IRHDR can provide a framework for future clinical trials, thus, creating excellent research opportunities. Lastly, a de-identified link between clinical data and companion biology studies can potentially be accomplished in the future through the IRHDR. This may further help in understanding the etiology of these rare diseases, as well as identifying potential therapeutic targets.

03

Conditions studied

  • Rare Histiocytic Disorders (RHDs)
  • Erdheim-Chester Disease (ECD)
  • Rosai-Dorfman Disease (RDD)
  • Xanthogranuloma Family (XG)
  • Indeterminate Dendritic Cell Histiocytosis
  • Malignant Histiocytic Neoplasm (MHN)
  • ALK-positive Histiocytosis
  • Mixed Histiocytosis (MXH)
  • Multicentric Reticulohistiocytoma (MRH)
  • Necrobiotic Xanthogranuloma (NX)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Rare Histiocytic Disorders:

  1. Xanthogranuloma Family (XG)

    • Cutaneous
    • Benign cephalic histiocytosis (BCH)
    • Generalized eruptive histiocytosis (GEH)
    • Progressive nodular histiocytosis (PNH)
    • Xanthoma disseminatum (XD)
    • Giant XG
    • Reticulohistiocytoma
    • Ocular
    • Systemic
  2. Erdheim-Chester Disease (ECD)
  3. Rosai-Dorfman disease (RDD)

    • Single system
    • Nodal
    • Extranodal
    • Skin
    • CNS
    • Bone
    • Orbit
    • Other
    • Multisystemic
  4. Indeterminate Dendritic Cell Histiocytosis
  5. Malignant Histiocytic Neoplasm (MHN)

    • Histiocytic
    • Langerhans cell
    • Interdigitating dendritic cell
    • Indeterminate dendritic cell
    • Primary MHN
    • Secondary to:
    • ALL
    • Follicular lymphoma
    • Other B-cell lymphoma
    • Other hematologic malignancy
    • Histiocytosis
  6. ALK-positive Histiocytosis
  7. Mixed Histiocytosis (MXH)

    • ECD/LCH
    • RDD/LCH
    • RDD/ECD
    • LCH/JXG
    • Other
  8. Other

    • Multicentric reticulohistiocytoma (MRH)
    • Necrobiotic xanthogranuloma (NX)
    • Not otherwise specified (NOS)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any age at diagnosis.
  2. Diagnosis of a rare histiocytic disorder, established before or after the opening of the registry.
  3. Cases diagnosed from January - 01- 1995 until the present time and prospectively.
  4. Signed by a patient, or parent/legal guardian.
  5. Cognitively impaired patients can be included after consent by legal guardian/parent.
  6. Deceased patients can be included if they are contacted at least 6 months after the death of their child and not on their child's birthday or anniversary of death.

Exclusion criteria

Exclusion Criteria:

  1. has not been signed.
  2. Diagnosis other than RHD.
  3. Cases diagnosed before the year 1995.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
400 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Interventions

  • OtherRegistry study

    No intervention.

06

What researchers measure

Primary outcomes

  1. Collecting data on disease presentation, treatments used and treatment outcomes over time for patients diagnosed with RHD to better understand the diseases and optimize the treatments.

    Collecting data on disease presentation, treatments used and treatment outcomes over time for patients diagnosed with RHD to better understand the diseases and optimize the treatments. Data will be analysed on average yearly, the registry will be ongoing for 10 years.

    Time frame: Data will be analysed on average yearly, the registry will be ongoing for 10 years.

Secondary outcomes

  1. Develop treatment guidelines for the RHD based on solid clinical trial data.

    Develop treatment guidelines for the RHD based on solid clinical trial data. Data will be analysed on average yearly, the registry will be ongoing for 10 years.

    Time frame: Data will be analysed on average yearly, the registry will be ongoing for 10 years.

07

Study locations

14 of 15 sites recruiting
08

References and documents

Publications

  • Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005 Sep;45(3):256-64. doi: 10.1002/pbc.20246. PubMed 15547923 ↗
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Sep 2028 and a completion of Sep 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 7, 2014
Start
Oct 2014
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: oversight details, site details and data sharing statement
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 3 other changes: oversight details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02285582
Responsible party
Oussama Abla (Staff Physician, The Hospital for Sick Children) — Principal investigator
First posted
Nov 7, 2014
Start date
Oct 2014
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Oussama Abla, MD
Contact
oussama.abla@sickkids.ca
416-813-7879 ext. 407879
Oussama Abla, MD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion